Abstract
This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents - cetuximab and panitumumab - employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens - FOLFIRI and FOLFOX - has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects.
Original language | English |
---|---|
Pages (from-to) | 64-69 |
Number of pages | 6 |
Journal | European Journal of Cancer, Supplement |
Volume | 6 |
Issue number | 14 |
DOIs | |
Publication status | Published - Oct 2008 |
Keywords
- Cetuximab
- Colorectal cancer
- Panitumumab
ASJC Scopus subject areas
- Cancer Research
- Oncology